Cargando…

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1

Immune checkpoints blockades have shown promising clinical effects in various malignancies, but the overall response rate is low. Here, the immune features are comprehensively characterized in >10 000 cancer patients from The Cancer Genome Atlas and significantly positive correlations are observe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hui, Kuang, Xinwei, Liang, Long, Ye, Youqiong, Zhang, YongChang, Li, Jialu, Ma, Fangyu, Tao, Juan, Lei, Guang, Zhao, Shuang, Su, Juan, Yang, Nong, Peng, Cong, Xu, Xiaowei, Hung, Mien‐Chie, Han, Leng, Liu, Hong, Liu, Jing, Chen, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Full Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816704/ https://www.ncbi.nlm.nih.gov/pubmed/33510997 http://dx.doi.org/10.1002/advs.202001596

Ejemplares similares

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1
por: Ye, Youqiong, et al.
Publicado: (2020)

Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma
por: Kuang, Xinwei, et al.
Publicado: (2017)

Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis
por: Lau, Poyee, et al.
Publicado: (2022)

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
por: Jiménez-Fonseca, Paula, et al.
Publicado: (2018)

Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model
por: Rayman, Patricia, et al.
Publicado: (2015)

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
por: Stacchiotti, Silvia, et al.
Publicado: (2012)

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
por: Gasent Blesa, Joan Manel, et al.
Publicado: (2009)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment
por: Hatipoglu, Gökçe, et al.
Publicado: (2015)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors
por: Wiedmann, Marcus W., et al.
Publicado: (2012)

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016)

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor
por: Schindler, E, et al.
Publicado: (2016)

DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
por: Chen, Baiwen, et al.
Publicado: (2022)

Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib
por: Fiorio Pla, Alessandra, et al.
Publicado: (2014)

Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors()
por: León-Mateos, L., et al.
Publicado: (2015)

Pneumatosis Cystoides Intestinalis Secondary to Sunitinib Treatment for Gastrointestinal Stromal Tumor
por: Asahi, Yoh, et al.
Publicado: (2018)

Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report
por: LIU, YAN, et al.
Publicado: (2013)

PK/PD modeling based on NO-ET homeostasis for improving management of sunitinib-induced hypertension in rats
por: Liu, Hao-chen, et al.
Publicado: (2020)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
por: Komatsu, Yoshito, et al.
Publicado: (2015)

Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity
por: Zheng, Shuang, et al.
Publicado: (2023)

Profiling of immune features to predict immunotherapy efficacy
por: Ye, Youqiong, et al.
Publicado: (2021)

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment
por: Jiang, Zhou, et al.
Publicado: (2020)

Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
por: Kim, Hyo-Sin, et al.
Publicado: (2014)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
por: Small, Jeffrey, et al.
Publicado: (2017)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
por: Blagoev, Krastan B., et al.
Publicado: (2013)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
por: Lin, Harrison Sicheng, et al.
Publicado: (2022)

Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor
por: Valdes-Socin, Hernan, et al.
Publicado: (2017)

Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133(+) cells in triple-negative breast cancer
por: Zhang, Danfang, et al.
Publicado: (2014)

Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature review
por: Zhang, Chunhui, et al.
Publicado: (2016)

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
por: Liu, Shujing, et al.
Publicado: (2017)

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report
por: Ruiz-Bañobre, Juan, et al.
Publicado: (2016)

Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer
por: Du, Yang, et al.
Publicado: (2017)

CTHRC1 and PD-1/PD-L1 expression predicts tumor recurrence in prostate cancer
por: Zhou, Qing, et al.
Publicado: (2019)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mpktddi7pr3vhjlc38gr4obvod